Biochemistry Core
- Institution
- SANFORD RESEARCH/USD, SD
- Principal investigator
- Kyle J Roux
- Funding
- $278K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY The Biochemistry Core supports projects associated with the Center for Pediatric Research by providing consultation and technical support for protein-protein interaction screening with BioID-based methods, as well as multi-analyte detection. The Core will continue to perform BioID and similar methods as a cutting-edge approach to screen for protein-protein interactions. The Core will continue to provide technical abilities and services for multi-analyte detection and quantification of proteins. The Core will also aid in the preparation of manuscripts and funding applications as they relate to the services provided. By providing these services in house, the Core will directly interface with the investigators during experimental design, protocol establishment, troubleshooting and execution as well as organize any further analysis outside of the Core. The purpose of the Biochemistry Core is to support the goals of its users, namely independent scientists studying the basis of pediatric health and disease and uncovering novel approaches to treatment. Through this purpose the Core will continue to not only propel the work of Center and other independent scientists forward but will do so in a sustainable manner for decades to come.
LOADING MOONBASE SCORE
Questions for SANFORD RESEARCH/USD
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Sanford Research/UsdNot yet scored
Center for Pediatric Research
Kyle J Roux · $1.2M · 2024–2029
- NIH · Sanford Research/UsdNot yet scored
Structure and Function Studies of GPCRome
Ikuo Masuho · $415K · 2025–2030
- NIH · Sanford Research/UsdNot yet scored
Probing the mechanisms of dependency underlying skeletal genetic pathways of p53 and Notch in the pathogenesis of osteosarcoma
Jianning Tao · $514K · 2025–2030